申请人:Behnke Mark L.
公开号:US20110172186A1
公开(公告)日:2011-07-14
The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.
本发明提供了化合物及其药学上可接受的组合物,包括任何式(I)、(II)、(III)、(IV)、(V)或(VI)或其亚类。本发明还提供了通过向需要治疗FAAH介导的疾病、疾病或病症的患者施用包含任何式(I)、(II)、(III)、(IV)、(V)或(VI)或其亚类的化合物或组合物的治疗有效量的方法。此外,本发明还提供了通过向需要抑制FAAH的患者施用包含任何式(I)、(II)、(III)、(IV)、(V)或(VI)或其亚类的化合物或组合物的治疗有效量的方法。